ACT

Arch Biopartners Inc ("Arch" or the "Company")(CNSX:ACH)(OTC:FOIFF) and its
subsidiary Arch Cancer Therapeutics ("ACT") today announced Arch scientists have
successfully completed proof of principle studies in the area of targeting brain
tumour initiating cells. This milestone is the result of the ongoing development
work conducted by Arch scientists within their respective laboratories at the
University of Calgary.


Following successful peer review, the Arch scientists intend to disclose the
details of their results in an academic publication. 


About Arch Cancer Therapeutics 

ACT is an Alberta corporation wholly owned by Arch Biopartners. ACT's objective
is to develop non-invasive diagnostic and therapeutic molecules for brain
cancer. These molecules are specialized peptides proprietary to ACT that
identify and target brain tumor initiating cells ("BTIC") and invasive brain
cancer cells that are not normally seen using current state of the art
diagnostic imaging techniques. 


ACT intends to develop BTIC targeting diagnostic and therapeutic agents to meet
significant unmet medical needs in the diagnosis and treatment of malignant
gliomas of the brain. 


About Arch Biopartners

Arch Biopartners is a portfolio based biotechnology company established to
develop new products and technology for sale to pharmaceutical and industrial
companies.


For more information on the Company, please consult the other public documents
filed on SEDAR at www.sedar.com. 


The Company's website address is: www.archbiopartners.com.

Forward-Looking Statements 

All statements, other than statements of historical fact, in this news release
are forward looking statements that involve various risks and uncertainties,
including, without limitation, statements regarding the future plans and
objectives of the Company. There can be no assurance that such statements will
prove to be accurate. Actual results and future events could differ materially
from those anticipated in such statements. These and all subsequent written and
oral forward-looking statements are based on the estimates and opinions of
management on the dates they are made and are expressly qualified in their
entirety by this notice. The Company assumes no obligation to update
forward-looking statements should circumstances or management's estimates or
opinions change.

(TSXV:ACT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

(TSXV:ACT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024